Bavarian Nordic A/S  

(Public, CPH:BAVA)   Watch this stock  
Find more results for BAVA
+3.50 (1.50%)
Feb 12 - Close
CPH real-time data - Disclaimer
Currency in DKK
Range 233.00 - 243.50
52 week 171.50 - 393.00
Open 235.00
Vol / Avg. 117,261.00/172,717.00
Mkt cap 6.63B
P/E 41.35
Div/yield     -
EPS 5.72
Shares 28.02M
Beta     -
Inst. own     -
Mar 9, 2016
Q4 2015 Bavarian Nordic A/S Earnings Release (Estimated) Add to calendar
Nov 18, 2015
Bavarian Nordic A/S at Jefferies Global Healthcare Conference

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -62.74% 2.13%
Operating margin -104.33% 1.37%
EBITD margin - 5.06%
Return on average assets -9.13% 1.55%
Return on average equity -15.01% 2.33%
Employees 408 -
CDP Score - -


Hejreskovvej 10A, Munkegaarde

Website links


Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.

Officers and directors

Gerard W. M. van Odijk M.D. Independent Chairman of the Board
Age: 58
Paul Chaplin Ph.D. President, Chief Executive Officer
Age: 48
Anders Gersel Pedersen M.D. Independent Deputy Chairman of the Board
Age: 64
Ole Larsen Chief Financial Officer, Executive Vice President
Age: 50
Claus Braestrup Ph.D. Independent Director
Age: 71
Erik Gregers Hansen Independent Director
Age: 63
Peter Kurstein Independent Director
Age: 59